Amy Jo Purvis
Acute Care · Los Angeles, CANPI 1467708156
Payments from drug & device makers
Across 52 payments — averaging $67.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$488
- Seagen Inc.$398
- GSK$388
- AstraZeneca$291
- Beigene USA, Inc.$277
- Bristol Myers Squibb$228
- plus $1K from 17 others
What the payments were for
- Consulting fees$38811%
- Food & beverage$3,01686%
- Education$893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 4 | $488 |
| Seagen Inc. | 5 | $398 |
| GSK | 1 | $388 |
| AstraZeneca | 3 | $291 |
| Beigene USA, Inc. | 2 | $277 |
| Bristol Myers Squibb | 10 | $228 |
| Clovis Oncology, Inc. | 2 | $167 |
| Johnson & Johnson | 2 | $158 |
| Ipsen Biopharmaceuticals, Inc | 1 | $135 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| AbbVie | 6 | $118 |
| Genmab U.S., Inc. | 1 | $118 |
| Jazz Pharmaceuticals Inc. | 1 | $116 |
| E.r. Squibb & Sons, L.L.C. | 1 | $114 |
| Lilly USA, LLC | 1 | $89 |
| Morphosys, US Inc. | 1 | $88 |
| Merck | 2 | $48 |
| Incyte Corporation | 2 | $40 |
| Gilead | 2 | $33 |
| Blueprint Medicines Corporation | 1 | $23 |
| Novartis | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,493 in reported general payments places this provider in the 90th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 12 | $536 |
Paid to pharmacies, not to this prescriber.
Other acute care in Los Angeles
- Frances DyLos Angeles$57K
- Kori Ann JohnstonLos Angeles$42K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
- Stacey GrossLos Angeles$22K
- Mary HuntsingerLos Angeles$12K
- Charlotte LipskyLos Angeles$10K
- Kimberly TranLos Angeles$8K
- Lisa YenLos Angeles$7K
- Rafael BegluyanLos Angeles$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.